scholarly journals Emerging Therapeutic Concepts and Latest Diagnostic Advancements Regarding Neuroendocrine Tumors of the Gynecologic Tract

Medicina ◽  
2021 ◽  
Vol 57 (12) ◽  
pp. 1338
Author(s):  
Tiberiu-Augustin Georgescu ◽  
Roxana Elena Bohiltea ◽  
Octavian Munteanu ◽  
Florentina Furtunescu ◽  
Antonia-Carmen Lisievici ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Neuroendocrine Carcinoma ◽  
Classification System ◽  
Who Classification ◽  
Small Cell ◽  
International Agency ◽  
Low Grade ◽  
High Grade ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Female Genital

Neuroendocrine neoplasms (NENs) are particularly rare in all sites of the gynecological tract and include a variety of neoplasms with variable prognosis, dependent on histologic subtype and site of origin. Following the expert consensus proposal of the International Agency for Research on Cancer (IARC), the approach in the latest World Health Organization (WHO) Classification System of the Female Genital Tumours is to use the same terminology for NENs at all body sites. The main concept of this novel classification framework is to align it to all other body sites and make a clear distinction between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). The previous WHO Classification System of the Female Genital Tumours featured more or less the same principle, but used the terms ‘low-grade neuroendocrine tumor’ and ‘high-grade neuroendocrine carcinoma’. Regardless of the terminology used, each of these two main categories include two distinct morphological subtypes: NETs are represented by typical and atypical carcinoid and NEC are represented by small cell neuroendocrine carcinoma (SCNEC) and large cell neuroendocrine carcinoma (LCNEC). High-grade NECs, especially small cell neuroendocrine carcinoma tends to be more frequent in the uterine cervix, followed by the endometrium, while low-grade NETs usually occur in the ovary. NENs of the vulva, vagina and fallopian tube are exceptionally rare, with scattered case reports in the scientific literature.

scholarly journals Synchronous endometrioid carcinoma of the endometrium and small cell neuroendocrine carcinoma of the cervix: a rare combination

2018 ◽  
pp. bcr-2018-227155
Author(s):  
Tripti Nakra ◽  
Rituparna Biswas ◽  
Rambha Pandey ◽  
Rajni Yadav
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Genital Tract ◽  
Female Genital Tract ◽  
Multimodality Treatment ◽  
Small Cell ◽  
Endometrioid Carcinoma ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Multiple Primaries ◽  
Tumour Bulk ◽  
Female Genital

Synchronous multiple primaries of female genital tract are uncommon, with the most frequently encountered combination being of endometrium and ovary. Concurrent primary tumours of endometrium and cervix are rare. We report a case of coexistent endometrioid carcinoma of the endometrium and small cell neuroendocrine carcinoma of the cervix in 48-year-old woman who presented with menometrorrhagia and was detected to have metastases to distant sites on imaging. She underwent multimodality treatment which resulted in a significant reduction in the tumour bulk.

Pulmonary Neuroendocrine Carcinomas

2002 ◽  
Vol 126 (5) ◽  
pp. 545-553 ◽  
Author(s):  
Qin Huang ◽  
Alona Muzitansky ◽  
Eugene J. Mark
Keyword(s):  
Neuroendocrine Tumors ◽  
Neuroendocrine Carcinoma ◽  
Large Cell ◽  
Small Cell ◽  
The Body ◽  
Low Grade ◽  
Typical Carcinoid ◽  
Poorly Differentiated Neuroendocrine Carcinoma ◽  
Poorly Differentiated ◽  
Neuroendocrine Carcinomas

Abstract Context.—Primary pulmonary neuroendocrine tumors are traditionally classified into 3 major types: typical carcinoid (TC), atypical carcinoid (AC), and large cell neuroendocrine carcinoma (LC) or small cell neuroendocrine carcinoma (SC). Confusion arises frequently regarding the malignant nature of TC and the morphologic differentiation between AC and LC or SC. Objective.—To provide clinicopathologic evidence to streamline and clarify the histomorphologic criteria for this group of tumors, emphasizing the prognostic implications. Patients.—To minimize variability in diagnostic criteria and treatment plans, we analyzed a group of patients whose diagnosis and treatment occurred at a single institution. We reviewed 234 cases of primary pulmonary neuroendocrine tumors and thoroughly studied 50 cases of resected tumors from 1986 to 1995. Results.—On the basis of morphologic characteristics and biologic behaviors of the tumors, we agree with many previous investigators that these tumors are all malignant and potentially aggressive. Based on our accumulated data, we have modified Gould criteria and reclassified these tumors into 5 types: (1) well-differentiated neuroendocrine carcinoma (otherwise called TC) (14 cases, with less than 1 mitosis per 10 high-power fields [HPF] with or without minimal necrosis); (2) moderately differentiated neuroendocrine carcinoma (otherwise called low-grade AC) (6 cases, with less than 10 mitoses per 10 HPF and necrosis evident at high magnification); (3) poorly differentiated neuroendocrine carcinoma (otherwise called high-grade AC) (10 cases, with more than 10 mitoses per 10 HPF and necrosis evident at low-power magnification); (4) undifferentiated LC (5 cases, with more than 30 mitoses per 10 HPF and marked necrosis); and (5) undifferentiated SC (15 cases, with more than 30 mitoses per 10 HPF and marked necrosis). The 5-year survival rates were 93%, 83%, 70%, 60%, and 40% for well, moderately, and poorly differentiated, and undifferentiated large cell and small cell neuroendocrine carcinomas, respectively. We found nodal metastasis in 28% of TC in this retrospective review, a figure higher than previously recorded. Conclusion.—Using a grading system and terms comparable to those used for many years and used for neuroendocrine tumors elsewhere in the body, we found that classification of pulmonary neuroendocrine carcinomas as well, moderately, poorly differentiated, or undifferentiated provides prognostic information and avoids misleading terms and concepts. This facilitates communication between pathologists and clinicians and thereby improves diagnosis and management of the patient.

Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer

Lung Cancer ◽  
2010 ◽  
Vol 68 (3) ◽  
pp. 438-445 ◽  
Author(s):  
Satoshi Igawa ◽  
Reiko Watanabe ◽  
Ichiro Ito ◽  
Haruyasu Murakami ◽  
Toshiaki Takahashi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Neuroendocrine Carcinoma ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
High Grade ◽  
Small Cell Lung ◽  
Small Cell Neuroendocrine Carcinoma

scholarly journals Urothelial carcinoma with villoglandular differentiation (UCVGD) with small cell neuroendocrine carcinoma of urinary bladder

2019 ◽  
Vol 12 (1) ◽  
pp. bcr-2018-228017 ◽  
Author(s):  
Shilpy Jha ◽  
Suvradeep Mitra ◽  
Amit Kumar Adhya ◽  
Prasant Nayak
Keyword(s):  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Male Patient ◽  
Neuroendocrine Carcinoma ◽  
Small Cell ◽  
High Grade ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Therapeutic Implications ◽  
Muscle Invasive ◽  
Aggressive Variant

Urothelial carcinoma with villoglandular differentiation (UCVGD) is a rare aggressive variant of urothelial carcinoma. It is usually associated with high-grade urothelial carcinoma or rarely adenocarcinoma. There is only one other previous report of UCVGD associated with small cell neuroendocrine carcinoma of urinary bladder. We report the second case of UCVGD with small cell neuroendocrine carcinoma of urinary bladder in a 74-year-old non-smoker male patient. The mass was muscle invasive and also invaded the prostate. This entity needs to be confidently diagnosed due to its prognostic and therapeutic implications.

scholarly journals Review of Small Cell Carcinomas of the Prostate

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
P. Furtado ◽  
M. V. A. Lima ◽  
C. Nogueira ◽  
M. Franco ◽  
F. Tavora
Keyword(s):  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Advanced Disease ◽  
Small Cell ◽  
High Grade ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Rare Neoplasm ◽  
Carcinoma Of The Prostate

Small cell carcinoma of the prostate is a rare neoplasm, with only a few series hitherto reported. A little less than half of the cases are associated with conventional acinar adenocarcinoma, which are usually high grade. Although consensus has not been reached, the majority of patients with small cell neuroendocrine carcinoma of the prostate have advanced disease at diagnosis and disproportionally low PSA levels compared to patients with conventional acinar adenocarcinoma. Treatment consists mainly of chemotherapy associated with surgery. Radiation therapy is reserved for selected cases. This study reviews the most up-to-date information on small cell carcinomas of the prostate.

scholarly journals High-grade Non-small Cell Neuroendocrine Carcinoma of the Esophagus

Cureus ◽  
2018 ◽  
Author(s):  
Stephen J Hjerpe ◽  
Umar Rahim ◽  
Muhammad Shariq Usman ◽  
Amna Ansari ◽  
Waliul Chowdhury ◽  
...  
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Small Cell ◽  
High Grade ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Carcinoma Of The Esophagus

scholarly journals Gallbladder Neuroendocrine Tumors (NETs): Is there a need for a specific approach?

2021 ◽  
Author(s):  
Vijay Waman Dhakre ◽  
Govind Purushothaman ◽  
Nilesh Doctor
Keyword(s):  
Neuroendocrine Tumors ◽  
Neuroendocrine Carcinoma ◽  
Biliary Tree ◽  
Small Cell ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Specific Approach ◽  
Results Of Treatment ◽  
Rare Tumours ◽  
Current Guidelines

Neuroendocrine tumors (NETS) of the Gallbladder or the biliary tree are rare. Most of the current guidelines and protocols are derived from the experience of managing Lung small cell neuroendocrine carcinoma (SCNEC) or gastrointestinal (GI) NETS. But the overall outcome of Gallbladder NETS (GB NETS) seems worse than similarly staged lung NETS and adenocarcinoma of the gallbladder. This may be due to its rarity and lack of literature for a focused approach towards its treatment. Hence the need for a specifically designed approach might help improve the results of treatment for these rare tumours. We share our experience of two patients with GB NETS and their 5-year outcome.

Carcinoma neuroendocrino esofágico de células pequeñas

2020 ◽  
Vol 50 (2) ◽  
Author(s):  
Tatiana Uehara ◽  
Juan Ignacio Olmos ◽  
Julieta Rodríguez Catán ◽  
Alejandra Avagnina ◽  
Pablo Antelo ◽  
...  
Keyword(s):  
Clinical Features ◽  
Neuroendocrine Carcinoma ◽  
Small Cell ◽  
Therapeutic Management ◽  
Published Data ◽  
High Grade ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Low Incidence

Primary small cell neuroendocrine carcinoma of the oesophagus are extremely rare. Histopathologically these are usually high grade proliferative tumours. Typical clinical features have not been described, nor has standard therapeutic management been established, due to low incidence and scarcity of published data. We describe the case of a patient admitted to our hospital for dysphagia and hematemesis, diagnosed with primary small cell neuroendocrine carcinoma of the oesophagus.

Sign in / Sign up

Export Citation Format

Share Document